Last checked at 1 Jul 2019 07:00
For immediate release | 1 July 2019 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Directorate Change
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that John Dawson, Non-Executive Director, Founder and former CEO of Alliance, has decided to step down from the Company's Board, effective from 30 June 2019, after 23 years of service.
John Dawson said: "The Company is in good hands with a strong Board following the planned Board changes over the past 12 months. As such, and in light of the fact that I will soon be participating in the 2019/20 Clipper Round the World Ocean Yacht Race, I have decided that it is time to move on. I would like to wish all at Alliance continued success in driving the Company forward."
David Cook, Alliance Pharma's Chairman, commented: "On behalf of the Board, I would like to thank John for his dedication, commitment and service to Alliance since he founded the Company in 1996, as both CEO and more recently as a Non-Executive Director. We wish him every success in his future endeavours."
Peter Butterfield, Alliance Pharma's CEO, commented: "It has been a real pleasure to have worked closely with John for over 10 years and to see the Company he founded go from strength to strength. I wish him all the best for the future."
For further information
Alliance Pharma plc | + 44 (0)1249 466966 |
Peter Butterfield, Chief Executive Officer | |
Andrew Franklin, Chief Financial Officer | |
www.alliancepharma.co.uk | |
Buchanan | + 44 (0)20 7466 5000 |
Mark Court / Sophie Wills / Hannah Ratcliff | |
Numis Securities Limited | + 44 (0)20 7260 1000 |
Nominated Adviser: Freddie Barnfield | |
Corporate Broking: James Black |
Investec Bank plc | + 44 (0) 20 7597 5970 |
Corporate Finance: Daniel Adams / Ed Thomas | |
Corporate Broking: Patrick Robb / Tejas Padalkar |
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.
We currently own or license the rights to more than 90 pharmaceutical and consumer healthcare products, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.
Our strategy allows us to benefit both from organic growth opportunities and from enhancing our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com